Skip to Content

New Drug Approvals Archive - January 2003

January 2003

Amevive (alefacept)

Date of Approval: January 30, 2003
Company: Biogen, Inc
Treatment for: Psoriasis

Amevive (alefacept) is a selective immunomodulating antipsoriatic agent used to treat moderate to severe chronic plaque psoriasis.

New Drug Approvals Archive

More News Resources

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.